Biogen Idec Inc . ( BIIB ) Deutsche Bank BioFEST Conference December ..... analyst at Deutsche Bank. Next we have Biogen Idec and I’m very pleased to have three members of the Biogen management team. We have Paul Clancy
After requesting additional information regarding "to the validation of a manufacturing step," the FDA has extended the PDUFA date for Biogen 's ( BIIB +1.4% ) hemophilia B treatment Alprolix. ( PR ) See also: Eloctate approval delayed Post your comment!
Dec 2 (Reuters) - Biogen Idec Inc on Monday said the U.S. Food and Drug Administration will extend by three months its deadline for reviewing the company's experimental long-acting medicine for...
times forward earnings respectively, Biogen ( BIIB +12.6% ) and Gilead ( GILD +3.5 ..... at these levels." Further gains for BIIB hinge on "a steady stream of good news ..... lock in gains. For the counterpoint on BIIB , see here . Post your comment!
Deutsche's Robyn Karnauskas is out with new numbers for Biogen ( BIIB +11.7% ) on the heels of the CHMP's decision to grant a NSA designation for Tecfidera . "Given the solid uptake ... in
Nov 22 (Reuters) - Biogen Idec Inc : * UBS raises target price to $300 from $265; rating neutral For a summary of rating and price target changes on U.S. companies
Biogen ( BIIB ) wins a new active substance designation for Tecfidera . Investors have been watching this ..... For more on why the decision was expected, see commentary from Wells Fargo out Thursday. BIIB +9% premarket Post your comment!
NEW YORK, Nov 22 (Reuters) - Biogen Idec Inc : * Up 10.1 percent to $278 in premarket; wins protection for MS drug in Europe
LONDON, Nov 22 (Reuters) - Biogen Idec has won regulatory protection for its top-selling multiple sclerosis drug Tecfidera in Europe, paving the way for its launch in markets that could account for a large proportion of future sales.
European Medicines Agency has granted Biogen Idec 's Tecfidera the new active substance ..... biggest near-term uncertainties for Biogen . We would have lowered our fair ..... oral MS drug competition. We think Biogen 's multiple sclerosis franchise